Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene

Editas Medicine, Inc.

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (World NEWSWIRE) — Immatics N.V. (Nasdaq: IMTX, “Immatics”), a medical-phase biopharmaceutical organization energetic in the discovery and enhancement of T cell-redirecting most cancers immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome enhancing enterprise, nowadays introduced that the two corporations have entered into a strategic investigate collaboration and licensing settlement to combine gamma-delta T cell adoptive cell therapies and gene modifying to create medications for the treatment method of cancer. As part of the licensing settlement, Immatics gains non-unique rights to Editas Medicine’s CRISPR know-how and intellectual assets. Editas Medicine is the special licensee of Harvard and Wide Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medications.

By combining Editas Medicine’s gene enhancing technological know-how with Immatics’ ACTallo® allogeneic, off-the-shelf adoptive cell remedy platform primarily based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets with the aim of generating cells with improved tumor recognition and destruction.

“Engineered cell therapies have the prospective to appreciably impact the treatment paradigm for cancer, and our partnership with the esteemed crew at Editas Drugs will deliver us with even more flexibility and overall flexibility in how we engineer our ACTallo® mobile therapies based on a certain tumor goal,” explained Rainer Kramer, Ph.D., Chief Company Officer, Immatics. “It has generally been our aim to provide innovative science to most cancers sufferers and this collaboration with Editas Medication will help us to obtain CRISPR technologies and implement them to our off-the-shelf gamma-delta T cell platform.”

“We think that our gene enhancing know-how can modulate and enhance the prospective of cell therapies to produce transformative medicines for the cure of cancer. We are fired up to function with the group at Immatics to create new experimental medications with improved tumor preventing skills to support individuals with most cancers,” stated Gilmore O’Neill, M.B., M.M.Sc., President and Main Government Officer, Editas Drugs.

Under the terms of the arrangement, Editas Medication will be eligible to obtain an undisclosed upfront income payment as effectively as supplemental milestone payments primarily based on enhancement, regulatory, and professional milestones. In addition, Immatics will shell out royalties on long run net revenue on any products and solutions that may perhaps result from this collaboration.

About Immatics
Immatics combines the discovery of legitimate targets for most cancers immunotherapies with the progress of the ideal T cell receptors with the aim of enabling a sturdy and unique T cell response from these targets. This deep know-how is the basis for our pipeline of Adoptive Mobile Therapies and TCR Bispecifics as effectively as our partnerships with global leaders in the pharmaceutical marketplace. We are dedicated to providing the electricity of T cells and to unlocking new avenues for clients in their combat from cancer.

For normal updates about Immatics, go to www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.

About Editas Medicine
As a leading genome editing firm, Editas Medicine is targeted on translating the electricity and probable of the CRISPR/Cas9 and CRISPR/Cas12a genome editing devices into a sturdy pipeline of treatment options for persons living with severe health conditions all over the globe. Editas Drugs aims to find, produce, manufacture, and commercialize transformative, long lasting, precision genomic medicines for a broad course of ailments. Editas Drugs is the exclusive licensee of Harvard and Wide Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the most recent information and facts and scientific shows, please visit www.editasmedicine.com.

Immatics Forward-On the lookout Statements
Certain statements in this press release may possibly be considered ahead-wanting statements. Ahead-looking statements normally relate to long term functions or Immatics’ upcoming financial or operating general performance. For illustration, statements about the timing of product candidates and Immatics’ emphasis on partnerships to advance its tactic are ahead-searching statements. In some circumstances, you can discover forward-searching statements by terminology this kind of as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or related terminology. This kind of ahead-looking statements are subject matter to threats, uncertainties, and other variables which could induce true benefits to differ materially from those expressed or implied by these types of forward on the lookout statements. These forward-looking statements are centered upon estimates and assumptions that, even though viewed as reasonable by Immatics and its administration, are inherently unsure. New dangers and uncertainties may perhaps arise from time to time, and it is not possible to predict all risks and uncertainties. Aspects that may possibly trigger true effects to differ materially from current anticipations involve, but are not restricted to, a variety of components beyond management’s management including standard economic situations and other threats, uncertainties and components set forth in filings with the SEC. Very little in this press release need to be regarded as a illustration by any human being that the forward-looking statements established forth herein will be attained or that any of the contemplated success of this kind of forward-hunting statements will be accomplished. You must not position undue reliance on ahead-hunting statements, which converse only as of the day they are created. Immatics undertakes no responsibility to update these forward-searching statements.

Editas Drugs Forward-On the lookout Statements
This press launch includes forward-wanting statements and data within the indicating of The Non-public Securities Litigation Reform Act of 1995. The text ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to detect forward-searching statements, whilst not all ahead-looking statements comprise these pinpointing text. Forward-hunting statements in this push launch consist of statements with regards to the predicted gains of Editas Medicine’s collaboration with Immatics, which include any long term payments it could acquire under the strategic investigation collaboration and licensing agreement and the potential to make medicines from the collaboration. Editas Medication may well not in fact realize the plans, intentions, or anticipations disclosed in these forward-searching statements, and you must not put undue reliance on these ahead-seeking statements. Real benefits or activities could differ materially from the programs, intentions and anticipations disclosed in these forward-on the lookout statements as a consequence of numerous components, such as: uncertainties inherent in the initiation and completion of pre-clinical research and clinical trials and scientific enhancement of Editas Medicine’s product candidates availability and timing of success from pre-medical reports and clinical trials no matter if interim effects from a scientific demo will be predictive of the final effects of the trial or the final results of long term trials anticipations for regulatory approvals to carry out trials or to market products and availability of funding ample for Editas Medicine’s foreseeable and unforeseeable functioning bills and cash expenditure needs. These and other pitfalls are explained in bigger detail under the caption “Risk Factors” incorporated in Editas Medicine’s most recent Yearly Report on Form 10-K, which is on file with the Securities and Trade Commission, as up-to-date by Editas Medicine’s subsequent filings with the Securities and Exchange Commission, and in other filings that Editas Medicine could make with the Securities and Trade Fee in the long run. Any ahead-looking statements contained in this press launch characterize Editas Medicine’s sights only as of the date hereof and really should not be relied upon as representing its sights as of any subsequent date. Apart from as needed by law, Editas Medicine explicitly disclaims any obligation to update any ahead-wanting statements.